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As this randomized controlled trial, through no fault of the investigators, has generated so much misunderstanding in regard to what may constitute any proper use of magnesium sulfate (MgSO 4 ) in the United States in the setting of preterm labor, my colleagues and I want to explore these matters in greater depth with the members of the American neonatal and perinatal medical community through the use of an attributable risk model.
In brief, the Australasian study reported that the occurrence of a secondary, composite variable defined as ''death or substantial motor dysfunction at a corrected age of 2 years'' was significantly lower in the MgSO 4 exposed group (RR, 0.75; 95% CI, 0.59 to 0.96). None of the primary outcomes was significant, although, for each group, the point estimates of the relative risks were lower in the MgSO 4 group. Concerning the essential primary variable, viz., cerebral palsy (CP), 6.8% (36 of 542) of those exposed to prophylactic MgSO 4 developed CP, whereas 8.2% (42 of 519) of non-magnesium-exposed controls were affected (not significant (RR 0.83, 0.54 to 1.27; p ¼ 0.38)). The absolute difference between the two groups was 1.4% (8.2À6.8% ¼ 1.4%), that is only six cases (42À36 ¼ 6) after more than 1000 randomizations in the two arms.
It is important to be aware that ACTOMgSO 4 was a preventive trial using comparatively low doses of magnesium. Thus, the results should not be generalized to the current USFand what turns out to be, non-evidence-basedFuse of MgSO 4 for tocolysis. In regimens being used in this country, 4 to 6 g loading doses (given over a short time interval) of MgSO 4 are followed by maintenance infusions ranging from 2 to 4 g per hour for 24 or more hours (52 to 102 g minimum total exposure), if not for substantially longer periods of time with larger cumulative exposures to MgSO 4 . Per the ACTOMgSO 4 research protocol, the maximum, total dose of MgSO 4 administered to any mother, hence baby, in the study was 28 g; however, only 70 of 522 subjects randomized to MgSO 4 actually received that amount. Indeed, the total median exposure to magnesium in the ACTOMgSO 4 study was about 11 gFmuch less than that used in this country for managing preterm labor. These differences are important since exposures to tocolytic dosages of MgSO 4 were found to be associated with a statistically significant increase in total pediatric mortality during the recent Cochrane Systematic Review (Dr. Crowther et al. 2 ). As we recently asked, 3 if the trends seen in ACTOMgSO 4 can be confirmed in other studies and, more importantly, shown to reach statistical significance (not yet achieved for the cerebral palsy variable), how is it that MgSO 4 could be both prophylactic against CP on the one hand, and yet lethal to susceptible fetuses on the other? While there may be other explanations, as mentioned in our previous correspondence, 3 we favor the often overlooked basic pharmacological principle that virtually all drugs work within a fairly narrow therapeutic window, requiring dosage limitations above which toxicity steadily increases in a dose-related fashion.
Using American demographics, and in view of the ACTOMgSO 4 findings, we took the liberty of applying our previously reported model 4 to estimate the potential neuroprotective benefits of MgSO 4 versus its current tocolytic usage. Approximately 28,000 very low birth weight (VLBW, <1500 g) babies are born every year in this country (prevalence of VLBW, 0.7% Â 4 million annual births ¼ 28,000). Current data suggest that about 80% of women having a diagnosis of preterm labor receive tocolysis. At least 80% of the total pediatric mortality found to be associated with MgSO 4 appears to occur among babies less than age 1 year, and the excess risk for death associated with the use of tocolytic MgSO 4 , according to meta-analysis, was predicted to be 10.7% (95% CI 3.9 to 17.6; p ¼ 0.002). 4 Thus, according to this model, the continued use of tocolytic magnesium in the US, at current doses, would lead to more than 1900 (28,000 Â 0.8 Â 0.8 Â 0.107 ¼ 1917) infant deaths annually. By comparison, in the same population, using the findings of ACTOMgSO 4 Fif they were to remain relevant at the higher tocolytic dosesFthe potential protective effect of MgSO 4 against CP would be predicted to be about 1.4% of those exposed (see above). Therefore, around 400 (28,000 Â 0.014 ¼ 392) children might be spared developing CP, at the human cost of the 1900 infants who would have perished following exposure to highdose tocolytic MgSO 4 . For perspective, it is worth noting that approximately 6000 new cases of congenital CP occur in the United States annually. Consequently, the theoretical reduction of 392 would decrease the total national incidence of CP by only 6.5% (392 of 6000 ¼ 6.5%). To us, in the broad context of the problem, this seems to be a small number.
Naturally, this public health problem might be circumvented if tocolytic MgSO 4 were abandoned in the United States, especially given the absence of any evidence basis to support its use for that purpose (see the expanded review of this topic by Pryde et al, 5 ). Conversely, the potential use of lower, subtoxic doses of MgSO 4 for the much needed purpose of cerebral protection in the setting of premature labor (assuming the work of Dr. Crowther and colleagues can be confirmed) is very exciting. Perhaps other trials currently underway will shed additional light on this intriguing subject. For now, we can only hope that such will be the case. Nonetheless, the continued use of high-dosage magnesium for tocolysis remains an overriding concern.
